| 1353 |
National Cancer Institute |
Html |
en |
Adult Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of adult non-Hodgkin lymphoma |
| indolent lymphoma | 0.429154 |
| PUBMED Ab | 0.422097 |
| mediastinal B-cell lymphoma | 0.454731 |
| Low-grade MALT lymphoma | 0.426029 |
| indolent follicular lymphoma | 0.463176 |
| Engl J Med | 0.422774 |
| International Lymphoma Study | 0.450979 |
| T-cell non-Hodgkin lymphoma | 0.425991 |
| advanced-stage follicular lymphoma | 0.451924 |
| Lymphoma Study Group | 0.535602 |
| large cell lymphoma | 0.468204 |
| peripheral t-cell lymphoma | 0.456381 |
| lymphoid tissue lymphoma | 0.492221 |
| B-cell gastric lymphoma | 0.454154 |
| large b-cell lymphoma | 0.673742 |
| low-grade follicular lymphoma | 0.465805 |
| Clin Lymphoma Myeloma | 0.48896 |
| gastric MALT lymphoma | 0.456031 |
| Follicular Lymphoma International | 0.455402 |
| diffuse large b-cell | 0.567142 |
| anaplastic large-cell lymphoma | 0.485835 |
| nodal follicular lymphoma | 0.485707 |
| Follicular Lymphoma Therapy | 0.460112 |
| marginal-zone B-cell lymphoma | 0.442434 |
| et al. | 0.657474 |
|
| follicular large-cell lymphoma | 0.442424 |
| advanced-stage non-Hodgkin lymphoma | 0.443686 |
| natural killer/t-cell lymphoma | 0.443936 |
| mucosa-associated lymphoid tissue | 0.475564 |
| PUBMED Abstract | 0.461097 |
| diffuse large-B-cell lymphoma | 0.442818 |
| primary follicular lymphoma | 0.490523 |
| low-grade gastric lymphoma | 0.426685 |
| mantle cell lymphoma | 0.422703 |
| follicular lymphoma | 0.604182 |
| Abstract | 0.663115 |
| lymphoplasmacytic lymphoma | 0.440428 |
| Clin Oncol | 0.941 |
| lymphoma | 0.746021 |
| international follicular lymphoma | 0.455144 |
| Low-Grade Lymphoma Study | 0.438252 |
| non-hodgkin lymphoma | 0.449125 |
| marginal zone lymphoma | 0.509105 |
| follicular lymphoma patients | 0.482999 |
| B-Cell Lymphoma Treated | 0.458319 |
| Systemic B-Cell Lymphoma | 0.432957 |
| MALT lymphoma | 0.489467 |
| Non-Hodgkin Lymphoma Study | 0.426008 |
| Lymphoma Classification Project | 0.46454 |
|
CLICK HERE |
| 1476 |
National Cancer Institute |
Html |
en |
Adrenocortical Carcinoma Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of adrenocortical carcinoma. |
| tumor marker | 0.675202 |
| out-of-phase T1-weighted imaging | 0.697012 |
| stage IV tumors | 0.659343 |
| metastatic functioning tumors | 0.801327 |
| staging tool | 0.722476 |
| PDQ cancer information | 0.856921 |
| metastatic lesions | 0.771984 |
| extracapsular tumor invasion | 0.747406 |
| staging systems | 0.691871 |
| potential lung metastasis | 0.731171 |
| adrenocortical carcinomas | 0.63434 |
| chemotherapeutic agent mitotane | 0.781817 |
| cancer information summary | 0.816255 |
| breast cancer prevention | 0.687711 |
| ENSAT staging | 0.713932 |
| mitotane antihormonal drugs | 0.805561 |
| malignant adrenal masses | 0.717902 |
| careful endocrine studies | 0.718613 |
| NCI’s PDQ | 0.665371 |
| PDQ Adult Treatment | 0.724299 |
| Proper staging | 0.693902 |
| NCI PDQ cancer | 0.764668 |
| Adrenal Tumors | 0.670042 |
| effective noninvasive method | 0.696617 |
| adrenal cancer | 0.657663 |
|
| radiation therapy | 0.69704 |
| long-term disease-free survival | 0.704486 |
| complete resection | 0.734805 |
| magnetic resonance imaging | 0.900392 |
| complete tumor resection | 0.779736 |
| excessive hormone production | 0.742148 |
| measurable tumor burden. | 0.740477 |
| steroid receptor antagonists | 0.687573 |
| hormone production | 0.798926 |
| 5-year survival | 0.724946 |
| National Cancer Institute | 0.688962 |
| le Cancer staging | 0.787658 |
| PDQ documents | 0.647653 |
| useful clinical responses | 0.679315 |
| adrenal mass. | 0.63451 |
| World Health Organization. | 0.685412 |
| measurable partial remissions | 0.680413 |
| adrenocortical carcinoma | 0.73628 |
| primary tumor | 0.750316 |
| adjuvant mitotane | 0.712566 |
| above-mentioned AJCC staging | 0.781955 |
| American Joint Committee | 0.694648 |
| regional lymph nodes | 0.695067 |
| Overall 5-year survival | 0.710773 |
|
CLICK HERE |
| 1486 |
National Cancer Institute |
Html |
en |
Melanoma Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of melanoma. |
| temozolomide versus dacarbazine | 0.706064 |
| standard therapy arm | 0.513108 |
| individual treatment sections | 0.538046 |
| single-agent inhibitor | 0.443006 |
| BRAF-mutated metastatic melanoma | 0.711751 |
| Val600 BRAF-mutant melanoma | 0.627182 |
| drug targets | 0.434691 |
| clinical trial design | 0.573658 |
| Drug Administration | 0.434687 |
| primary endpoint | 0.423708 |
| DTIC | 0.525789 |
| MEK inhibitor | 0.453277 |
| rare CRs | 0.424667 |
| active moiety | 0.422545 |
| randomized trials. | 0.46852 |
| BRAF-mutant subtype | 0.57943 |
| phase III study | 0.513517 |
| important option | 0.423407 |
| phase iii trials | 0.549837 |
| oral alkylating agent | 0.523779 |
| clinical trials | 0.434562 |
| V600 mutant melanoma | 0.640167 |
| sample size | 0.421859 |
|
| palliative radiation therapy | 0.502761 |
| multicenter trial | 0.445549 |
| temozolomide group | 0.594959 |
| multiagent chemotherapy | 0.434715 |
| randomized trial | 0.479926 |
| first-line vs. | 0.432084 |
| Clin Oncol | 0.536064 |
| Combination therapies | 0.426982 |
| genomic subtypes | 0.583162 |
| superior OS | 0.42215 |
| recent registration trials | 0.531572 |
| guide clinical decision-making | 0.554726 |
| Grob JJ | 0.535846 |
| High-dose recombinant interleukin | 0.518234 |
| ECOG PS | 0.423492 |
| randomised phase | 0.46148 |
| metastatic melanoma | 0.981501 |
| previously untreated patients | 0.74564 |
| primary endpoints | 0.427198 |
| metastatic malignant melanoma | 0.829145 |
| stage IV melanoma | 0.540818 |
| U.S. Food | 0.438775 |
|
CLICK HERE |
| 1519 |
National Cancer Institute |
Html |
en |
Rectal Cancer Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of rectal cancer. |
| cancer treatment | 0.518883 |
| body | 0.520416 |
| PDQ cancer information | 0.52558 |
| clinical trial search | 0.497998 |
| new blood vessels | 0.485963 |
| Digital rectal exam | 0.48424 |
| clinical trials | 0.752809 |
| nearby lymph nodes | 0.622455 |
| cancer information summary | 0.505272 |
| clinical trial | 0.589481 |
| Rectal Cancer Treatment | 0.502419 |
| colorectal cancer | 0.509773 |
| patients | 0.475547 |
| metastatic rectal cancer | 0.496375 |
| vascular endothelial growth | 0.472356 |
| NCI PDQ cancer | 0.475491 |
| malignant tumor cells | 0.468557 |
| radiation therapy | 0.598557 |
| rectum | 0.694659 |
| treatment | 0.642215 |
| Recurrent rectal cancer | 0.514414 |
| nonpolyposis colorectal cancer | 0.478736 |
| nearby organs | 0.553031 |
| cancer prevention | 0.463023 |
|
| new cancer treatments | 0.468973 |
| NCI-supported cancer | 0.477253 |
| cancer cells | 0.703626 |
| entire rectum | 0.4751 |
| Cancer Information Service | 0.470531 |
| muscle layer | 0.486714 |
| specific cancer cells | 0.477097 |
| endothelial growth factor | 0.47057 |
| treatment clinical trials | 0.482164 |
| National Cancer Institute | 0.505951 |
| outermost layer | 0.501883 |
| new treatment | 0.500006 |
| rectal cancer spreads | 0.494951 |
| Colorectal Cancer section | 0.478726 |
| rectal cancer | 0.877471 |
| rectum wall | 0.683123 |
| Blood. The cancer | 0.463452 |
| cancer research process | 0.463813 |
| cancer clinical trials | 0.522705 |
| stage | 0.526305 |
| tumor | 0.468782 |
| cancer information summaries | 0.468811 |
| comprehensive cancer information | 0.46866 |
| cancer | 0.995137 |
|
CLICK HERE |
| 1583 |
National Cancer Institute |
Html |
null |
Childhood Liver Cancer Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of childhood liver cancer. |
|
|
CLICK HERE |
| 1679 |
National Cancer Institute |
Html |
en |
Communication in Cancer Care (PDQ®)–Patient Version |
It is important to talk to your doctor about your cancer diagnosis, goals of treatment, plan of care, and what to expect over time. Learn how good communication between patients, families, caregivers and doctors can improve the patient's quality of life in this expert-reviewed summary. |
| cancer treatment | 0.389842 |
| bad news | 0.386292 |
| questions | 0.399361 |
| PDQ cancer information | 0.624305 |
| health care team | 0.981737 |
| clinical trials | 0.514782 |
| Pediatric Supportive Care | 0.404638 |
| communication | 0.486074 |
| cancer information summary | 0.515585 |
| clinical trial | 0.495706 |
| family members | 0.426143 |
| cancer care | 0.778281 |
| breast cancer prevention | 0.399685 |
| PDQ summaries | 0.394467 |
| patients | 0.573309 |
| cancer patients | 0.414288 |
| team share information | 0.427277 |
| latest published information | 0.403211 |
| NCI’s PDQ | 0.394236 |
| PDQ summary Family | 0.458483 |
| NCI PDQ cancer | 0.456705 |
| supportive care | 0.443184 |
| treatment | 0.599848 |
| family caregivers | 0.667411 |
|
| cancer prevention | 0.402033 |
| Cancer Information Service | 0.427003 |
| Explain medical information | 0.409499 |
| PDQ Supportive | 0.391221 |
| patient | 0.679815 |
| PDQ Communication | 0.403164 |
| treatment clinical trials | 0.401111 |
| National Cancer Institute | 0.597923 |
| decisions | 0.454448 |
| PDQ documents | 0.390179 |
| Palliative Care Editorial | 0.462952 |
| medical information | 0.462988 |
| new treatment | 0.398754 |
| good communication | 0.425774 |
| Cancer Care page | 0.429643 |
| PDQ database | 0.392979 |
| Care Editorial Board | 0.465833 |
| PDQ summary | 0.483184 |
| doctor | 0.450453 |
| cancer clinical trials | 0.415988 |
| cancer information summaries | 0.432334 |
| comprehensive cancer information | 0.43347 |
| cancer patient | 0.392432 |
| cancer | 0.840307 |
|
CLICK HERE |
| 1760 |
National Cancer Institute |
Html |
en |
Obesity and Cancer |
A fact sheet that summarizes the evidence linking overweight and obesity to the risk of various cancers and to cancer survivorship. |
| obesity causes cancer | 0.394065 |
| normal-weight people | 0.279732 |
| observational studies | 0.323456 |
| obesity prevalence | 0.293137 |
| obesity | 0.638496 |
| thyroid cancer risk | 0.290632 |
| obese people | 0.350767 |
| risk factors | 0.298103 |
| multiple myeloma | 0.271306 |
| colorectal cancer | 0.326707 |
| ovarian cancer | 0.293192 |
| body mass index | 0.723663 |
| prostate cancer risk | 0.293391 |
| postmenopausal breast cancer | 0.29585 |
| weight loss | 0.380764 |
| endometrial cancer increases | 0.279353 |
| cancer incidence data | 0.260252 |
| different cancer risk | 0.325913 |
| breast cancer survivors | 0.303032 |
| kidney cancer | 0.323356 |
| endometrial cancer | 0.299756 |
| invasive breast cancer | 0.260923 |
| menopausal hormone therapy | 0.326286 |
| women | 0.298824 |
| gallbladder cancer | 0.347557 |
|
| United States | 0.307003 |
| weight gain | 0.259995 |
| male breast cancer | 0.288797 |
| breast cancer diagnosis | 0.278716 |
| pancreatic cancer | 0.309076 |
| different cancer types | 0.265661 |
| LeRoith D. Obesity | 0.262512 |
| National Cancer Institute | 0.329185 |
| extremely obese women | 0.271426 |
| renal cell cancer | 0.355343 |
| increase cancer risk | 0.312393 |
| breast cancer risk | 0.439989 |
| breast cancer | 0.64758 |
| C. Gallbladder cancer | 0.256715 |
| cancer survivorship | 0.270564 |
| prostate cancer | 0.294021 |
| Breast Cancer WEight | 0.309447 |
| pancreatic cancer risk | 0.295039 |
| breast cancer pooling | 0.266031 |
| prospective studies | 0.320099 |
| et al | 0.828361 |
| cancer risk | 0.662021 |
| cancer | 0.97959 |
| liver cancer | 0.398322 |
|
CLICK HERE |
| 1809 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de pulmón de células pequeñas (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de pulmón de células pequeñas. |
| Lung Cancer Cooperative | 0.40923 |
| small-cell carcinoma | 0.409726 |
| Arriagada R | 0.406258 |
| mortality from lung | 0.406031 |
| Pignon JP | 0.406568 |
| lung carcinoma | 0.415433 |
| chemotherapy with or | 0.407857 |
| thoracic irradiation | 0.411758 |
| lung cancer | 0.99158 |
| small-cell lung | 0.732567 |
| American Cancer Society | 0.407972 |
| limited-stage small-cell lung | 0.528108 |
| with once-daily thoracic | 0.405556 |
| Cancer Data Base | 0.408315 |
| tobacco-specific lung carcinogen | 0.40968 |
| Lung Oncology Group | 0.405386 |
| Radiat Oncol Biol | 0.407067 |
| Lung Cancer Group | 0.40944 |
| oncology group study | 0.409486 |
| Natl Cancer Inst | 0.413727 |
| Council Lung Cancer | 0.408713 |
| patients with | 0.422455 |
| cancer lung | 0.415587 |
| Does thoracic irradiation | 0.406837 |
| small cell carcinoma | 0.40583 |
|
| small-cell lung carcinoma | 0.412738 |
| childhood cancer | 0.406909 |
| with small-cell lung | 0.428402 |
| Lung Cancer Working | 0.414426 |
| National Cancer | 0.425705 |
| extensive small-cell lung | 0.412452 |
| Clinical Trials Group | 0.406926 |
| small cell lung | 0.507254 |
| National Cancer Institute | 0.418442 |
| prophylactic cranial irradiation | 0.410926 |
| combination chemotherapy with | 0.405558 |
| with combination chemotherapy | 0.405558 |
| National Cancer Data | 0.408383 |
| Clin Oncol | 0.533689 |
| Oncol Biol Phys | 0.407177 |
| combined modality treatment | 0.409248 |
| Low-dose lung | 0.405724 |
| Canada Clinical Trials | 0.406735 |
| treated with | 0.408022 |
| Cancer Working Party | 0.407006 |
| with or without | 0.405778 |
| lung tumours | 0.405564 |
| Cancer Survivor Study | 0.405383 |
| thoracic radiotherapy | 0.433304 |
|
CLICK HERE |
| 2061 |
National Cancer Institute |
Html |
es |
Mamografías |
Hoja informativa que define las mamografías de detección y de diagnóstico; trata de los beneficios y perjuicios posibles de las mamografías de detección; y resume cómo se reportan los resultados, incluso la densidad de los senos. |
| largo perÃodo | 0.329403 |
| federal affordable care | 0.358034 |
| mamografÃa digital | 0.901811 |
| Database System | 0.32976 |
| de estudios clÃnicos aleatorizados y | 0.369135 |
| técnica especial llamada | 0.347452 |
| programa brinda servicios | 0.346724 |
| posibles limitaciones | 0.337532 |
| rayos x | 0.327782 |
| breast self-exam | 0.336335 |
| CategorÃa Evaluación Seguimiento | 0.350863 |
| posibles perjuicios | 0.338669 |
| alta densidad | 0.339314 |
| tratamiento. Las mamografÃas | 0.58289 |
| pequeñas masas | 0.327877 |
| Exposición a radiación. Las mamografÃas | 0.580742 |
| Resultado benigno | 0.343535 |
| Breast Imaging Reporting | 0.356725 |
| pequeños depósitos de calcio | 0.365542 |
| Colegio Estadounidense | 0.332034 |
| seguro médico | 0.544063 |
|
| mujeres con implantes | 0.382313 |
| detección temprana | 0.693756 |
| Healthcare Research | 0.333438 |
| al feto en crecimiento | 0.333178 |
| casos de carcinoma | 0.332936 |
| Instituto Nacional | 0.371979 |
| Mammography Quality Standards | 0.352873 |
| mujer nota | 0.33784 |
| normales aun | 0.335316 |
| tanta rapidez | 0.335356 |
| usa luz | 0.328978 |
| 3D usa dosis | 0.354905 |
| Requiere biopsia | 0.343563 |
| Estados Unidos | 0.809815 |
| pequeñas de radiación | 0.330854 |
| Cuello Uterino | 0.329522 |
| posibles beneficios | 0.33135 |
| positivos falsos. Los resultados | 0.376938 |
| ley mqsa | 0.332395 |
| decisiones médicas que | 0.334533 |
| mujeres jóvenes | 0.457334 |
|
CLICK HERE |
| 15649 |
National Cancer Institute |
Html |
en |
Genomic Data Sharing (GDS) Policy |
The NIH Genomic Data Sharing (GDS) Policy was issued to promote broad sharing of genomic research data and ensure oversight and protections for research involving human data. |
| Policy | 0.279904 |
| GDS | 0.601385 |
|
| National Cancer Institute | 0.917963 |
| Genomic Data | 0.846899 |
|
CLICK HERE |